AbbVie at ASCO: Early-Stage Data on ABT-414 and Rova-T - Zacks.com

Business Insider

AbbVie at ASCO: Early-Stage Data on ABT-414 and Rova-T Zacks.com AbbVie Inc. (ABBV - Analyst Report) was present at the ongoing annual meeting of the American Society of Clinical Oncology (ASCO) with early-stage data on a couple of its pipeline candidates - ABT-414 and rovalpituzumab tesirine (Rova-T). Both are ... Novel targeted drug shows promise against advanced small cell lung cancerEurekAlert (press release) Battleground: Analysts Diverge On AbbVie After Cancer Drug DataTheStreet.com Cowen Cuts Abbvie (ABBV) to Market Perform; Analyst Calls Rova-T Data at ASCO 'Underwhelming'StreetInsider.com Crain's Chicago Business -Barron's (blog) -Investor's Business Daily -BioPharma Dive all 21 news articles »

from Health - Google News http://news.google.com/news/url?sa=t&fd=R&ct2=us&usg=AFQjCNE_qGz4ROFKLodL8VKOUHxUWJrS6A&clid=c3a7d30bb8a4878e06b80cf16b898331&cid=52779127410816&ei=bJdVV4mhAoXg3gG9p6SQAw&url=https://www.zacks.com/stock/news/219468/abbvie-at-asco-earlystage-data-on-abt414-and-rovat
via IFTTT